Shots:
- Health Canada has approved Blenrep + BorDex & PomDex in MM pts with ≥1 prior therapy
- Approval was based on P-III (DREAMM-7 & DREAMM-8) trials assessing Blenrep + BorDex vs Darzalex + BorDex in 494 pts & Blenrep + PomDex (BPd) vs Velcade + PomDex in 302 pts, respectively
- DREAMM-7 showed improved PFS (1EP; mPFS: 36.6 vs 13.4mos.), depicting a 43% reduced death risk, while DREAMM-8 showed improved PFS by 48%, with unreached mPFS vs 12.7mos. at mFU of 21.8mos., whereas mPFS was 32.6 vs 12.5mos. at mFU of 28.01mos.
Ref: GSK | Image: GSK | Press Release
Related News:- The US FDA Approves GSK’s Shingrix Prefilled Syringe Presentation to Protect Individuals Against Shingles
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
